Premium
Effect of haemodialysis on serum levels of tumour markers in patients with end‐stage renal failure
Author(s) -
GERAKIS Alexandros,
BARBATSI Angeliki,
SARANTI Sophia,
STROGYLOU Theodora,
VALIS Dimitrios
Publication year - 1998
Publication title -
nephrology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.752
H-Index - 61
eISSN - 1440-1797
pISSN - 1320-5358
DOI - 10.1111/j.1440-1797.1998.tb00379.x
Subject(s) - medicine , carcinoembryonic antigen , enolase , malignancy , dialysis , prostate specific antigen , gastroenterology , stage (stratigraphy) , antigen , end stage renal disease , renal cell carcinoma , urology , hemodialysis , prostate , immunology , cancer , immunohistochemistry , paleontology , biology
SUMMARY: We studied the effect of haemodialysis on the serum levels of tumour markers in 78 patients, 49 men and 29 women with a mean age of 61 ± 2 years, who had been undergoing haemodialysis for 39 ± 10 months. No patient had any clinical evidence of malignancy. Serum values of carcinoembryonic antigen (CEA), alpha‐fetoprotein (AFP), squamous‐cell‐carcinoma‐related antigen (SCC), neuron‐specific enolase (NSE), tissue polypeptide antigen (TPA), CA 15‐3, CA 19–9, and among males prostate‐specific antigen (PSA) were determined before and after dialysis. Postdialysis values, after being corrected for haemoconcentration, were compared with predialysis values. A significant increase of 32% was observed in NSE levels ( P <0.001) and of 21% in CA 15‐3 ( P <0.001) after haemodialysis. A lesser, but still statistically significant, increase (8‐12%) was observed in SCC, AFP and CEA levels ( P <0.05), while the values of the remaining three markers remained unchanged. In conclusion, an increase in some tumour markers was found in our patients after dialysis, a finding which requires further investigation.